Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of Texas at Austin
Headquarters: Austin, TX, United States of America
Website: https://www.utexas.edu/
Year Founded: 1881
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Jan 12, 2024
Politics, Policy & Law
States allowed to intervene in case threatening integrity of FDA drug regulation
Texas judge allows three states to intervene in abortion drug case, potentially giving it a second life
BioCentury | Dec 12, 2023
Distillery Therapeutics
MTA depletion to overcome immunotherapy resistance in MTAP-deficient tumors
BioCentury | Oct 10, 2023
Emerging Company Profile
Hyku: tapping new targets by taking chemoproteomics beyond cysteine
In co-leading Hyku’s $56M seed round, RA Capital added to its portfolio of chemoproteomics companies
BioCentury | Aug 13, 2022
Discovery & Translation
IL-13-mutein CAR Ts; plus mAbs for metapneumovirus and more
BioCentury’s roundup of translational news
BioCentury | Mar 24, 2022
Discovery & Translation
IDO thwarts antitumor T cell responses; plus Lumen, Loki, Genentech and more
BioCentury’s roundup of translational news
BioCentury | Oct 27, 2021
Distillery Therapeutics
A mAb targeting a SARS-CoV-2 epitope conserved across variants
BioCentury | Aug 1, 2020
Emerging Company Profile
VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology
ExeVir emerges with llama-based antibody platform, 1st program for COVID-19
BioCentury | May 9, 2020
Translation in Brief
Antigens for COVID-19 serological testing; plus mapping glycans on SARS-CoV-2 spike, tumor sampling method and therapy for Parkinson’s
BioCentury’s roundup of preclinical news
Items per page:
1 - 10 of 48